Pinetree Therapeutics Announces Exclusive Option and Global License Agreement for Preclinical EGFR Degrader Candidate with AstraZeneca

Pinetree to receive up to $45 million in upfront and near-term payments, with a total deal value of over$500 million including potential additional development and commercial milestone payments CAMBRIDGE, Mass., July 23, 2024 /PRNewswire/ -- Pinetree Therapeutics, Inc. ("Pinetree" or the "Company"), a biotechnology company pioneering next generation targeted protein degraders (TPD) to combat drug resistance in oncology and beyond, today announced it has entered into an exclusive option and global license a ...